公开(公告)号：US10683287B2

公开(公告)日：2020-06-16

申请号：US16378887

申请日：2019-04-09

Applicant: Novartis AG

Inventor： Sangamesh Badiger ,  Murali Chebrolu ,  Konstanze Hurth ,  Sebastien Jacquier ,  Rainer Martin Lueoend ,  Rainer Machauer ,  Heinrich Rueeger ,  Marina Tintelnot-Blomley ,  Siem Jacob Veenstra ,  Markus Voegtle

IPC: C07D413/04 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  A61K31/5377 ,  C07B59/00

Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.

公开(公告)号：US20190062319A1

公开(公告)日：2019-02-28

申请号：US16020212

申请日：2018-06-27

Applicant: Novartis AG

Inventor： Sangamesh Badiger ,  Murali Chebrolu ,  Konstanze Hurth ,  Sebastien Jacquier ,  Rainer Martin Lueoend ,  Rainer Machauer ,  Heinrich Rueeger ,  Marina Tintelnot-Blomley ,  Siem Jacob Veenstra ,  Markus Voegtle

IPC: C07D413/14 ,  C07D487/04 ,  C07D471/04 ,  A61K31/5377 ,  C07B59/00

Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.

公开(公告)号：US10035794B2

公开(公告)日：2018-07-31

申请号：US15385147

申请日：2016-12-20

Applicant: NOVARTIS AG

Inventor： Sangamesh Badiger ,  Murali Chebrolu ,  Konstanze Hurth ,  Sebastien Jacquier ,  Rainer Martin Lueoend ,  Rainer Machauer ,  Heinrich Rueeger ,  Marina Tintelnot-Blomley ,  Siem Jacob Veenstra ,  Markus Voegtle

IPC: C07D413/14 ,  C07D487/04 ,  C07D471/04 ,  A61K31/5377 ,  C07B59/00

Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.

公开(公告)号：US20200048236A1

公开(公告)日：2020-02-13

申请号：US16378887

申请日：2019-04-09

Applicant: Novartis AG

Inventor： Sangamesh Badiger ,  Murali Chebrolu ,  Konstanze Hurth ,  Sebastien Jacquier ,  Rainer Martin Lueoend ,  Rainer Machauer ,  Heinrich Rueeger ,  Marina Tintelnot-Blomley ,  Siem Jacob Veenstra ,  Markus Voegtle

IPC: C07D413/14 ,  C07D471/04 ,  A61K31/5377 ,  C07D487/04

Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.

公开(公告)号：US12083101B2

公开(公告)日：2024-09-10

申请号：US17201268

申请日：2021-03-15

Applicant: Novartis AG

Inventor： Vincent Bordas ,  Cara Brocklehurst ,  Patrick Chene ,  Pascal Furet ,  Vito Guagnano ,  Patricia Imbach-Weese ,  Joerg Kallen ,  Mickael Le Douget ,  Edwige Liliane Jeanne Lorthiois ,  Joseph McKenna ,  Bahaa Salem ,  Tobias Schmelzle ,  Holger Sellner ,  Nicolas Soldermann ,  Markus Voegtle ,  Markus Wartmann

IPC: A61K31/4155 ,  A61K31/343 ,  A61K31/351 ,  A61K31/357 ,  A61K31/4025 ,  A61K31/403 ,  A61K31/404 ,  A61K31/41 ,  A61K31/426 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/4525 ,  A61K31/506 ,  A61P35/00 ,  C07D307/81 ,  C07D401/14 ,  C07D403/04 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D405/14 ,  C07D407/04 ,  C07D407/12 ,  C07D413/04 ,  C07D417/04 ,  C07D491/04

CPC classification number: A61K31/4155 ,  A61K31/343 ,  A61K31/351 ,  A61K31/357 ,  A61K31/4025 ,  A61K31/403 ,  A61K31/41 ,  A61K31/426 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/4525 ,  A61K31/506 ,  A61P35/00 ,  C07D307/81 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D407/04 ,  C07D407/12 ,  C07D417/04

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof;






a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

公开(公告)号：US10301296B2

公开(公告)日：2019-05-28

申请号：US16020212

申请日：2018-06-27

Applicant: Novartis AG

Inventor： Sangamesh Badiger ,  Murali Chebrolu ,  Konstanze Hurth ,  Sebastien Jacquier ,  Rainer Martin Lueoend ,  Rainer Machauer ,  Heinrich Rueeger ,  Marina Tintelnot-Blomley ,  Siem Jacob Veenstra ,  Markus Voegtle

IPC: C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  A61K31/5377 ,  C07B59/00

Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.